Juan Carlos Jaramillo

Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

Rajeka Lazarus, Benedicte Querton, Irena Corbic Ramljak et al. · The Lancet Infectious Diseases · 2022 · 47 citations · Full text

A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults

Robert P. McMahon, Ulrike Fuchs, Martina Schneider et al. · Journal of Travel Medicine · 2023 · 32 citations · Full text

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents

Vera Buerger, Sandra Hadl, Martina Schneider et al. · The Lancet Infectious Diseases · 2024 · 28 citations

Vaccination, Vaccine Safety, Vaccine Development +8

Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial

Christian Taucher, Rajeka Lazarus, Hanna Dellago et al. · Journal of Infection · 2023 · 14 citations · Full text

Vaccination, Vaccine Safety, Interim Analysis +11